Fred- I am sorry but that analyst at Maxim is smoking crack... If all three MNK partnered drugs hit market before end of 2017, then we might be able to hit total revenue of $25M with an outside chance at $30M. Realistically with just Seroquel and Focalin on the market, IPCI can hit total revenues of $15-20M. I find these Maxim reports shady and suspicious and I have a feeling there are ulterior motives... I am guessing they use the numbers to allow people to short sell prior to earnings and then take a nice easy 10% when they drive it down on the miss.

Fabius- My guess at this point is they just remove the blue dye and proceed with the other tests. All that being said... My guess is they could launch mid 2019. That timeframe allows for testing, resubmittal of data/application, getting a partner/manufacturer lined up and working out Purdue litigation.

A couple things:

1. The CRL called for a path forward. So I think it is reasonable that IPCI can meet those demands and Rexista could be on the market in mid 2019.
2. Q3 earnings will show improvement but not meet analysts expectations. They will come in roughly $2M- or less than half what analysts are calling for.
3. I expect more ANDA approvals this year. And at least one of the MNK partnered drugs will be approved.
4. I see IPCI being cash flow positive throughout 2018. Maybe even making a little money in Q4 2017.

Good luck everyone.

The talk about buyout and partnership is ridiculous. Tentative approval is possible but long shot. My guess is CRL or a path forward communication that will say:

1. Blue dye can be removed or left in. If left in additional safety test support by HAP tests or other is required.
2. HAP tests need to be completed for oral and nasal modes of abuse.

My guess is company is crafting PR this weekend and will let everyone know on Monday.

Good luck all. I won't be around waiting for FDA response as I am going fishing! Will be back Monday. Wish everyone the best.

Angelo- I will not give out where I got this information from. But I do not believe you know this individual. Yes this is second hand info... What I heard is that one of the law firms involved in the class action suit is investigating trading records on IPCI. What I was told is that they are in the process of identifying individuals, entities, etc that traded IPCI in large volume on a regular basis. They are then going to assess if any of these individuals/entities violated the law. That is what I know... Believe it if you want to or don't believe it...

Litigation in regards to IPCI will be very interesting... From what I heard there may be surprises in store. This is just a rumor I heard and nothing is substantiated. But if what I am hearing is true... Some real fireworks ahead! Stay tuned! The one thing I will say is what I have heard is not a negative for the company or shareholders.

I am glad to see that a few still believe in Rexista.

All I know is there may be a silver lining in these lawsuits!

One interesting rumor I heard is that part of the lawsuits will bring the manipulators of the share price into them. Just a rumor I heard but could be a little interesting when lawyers start subpoenaing trading transactions, website transcripts, etc.

Fred- I like your list. But do you really believe Purdue will be the Rexista partner?

Fred- I agree. Like you said, some dilution is inevitable. But hopefully they are smart about it. Hopefully they have other options. I have ben telling everyone be cautious and wait to buy. Anyone telling us to buy right now or that it is a good time to buy is one of the people that is trying to sell you shares in the 90 cent range now. These guys know full well that they plan to drive this down on Rexista news, missed earnings, etc. Yes, earnings will show improvement, but the headline will be IPCI misses by X... So if you really intend to buy, wait a few days and see what happens.

wimike- One of the questions I was asked was how I felt they were doing with partnerships. Please take the survey. I also made very clear that they better not go out and raise $5M at this level.

I know this survey will cost a little. But I think it a great move in the right direction. This is everyone's chance to have IPCI management hear their opinions.

Great job Doog! Other shareholders please call Abby at 403-218-2887 and do the survey! Excellent set of questions very pertinent to our concerns.

If any shareholders would like to participate in an IPCI sponsored survey. Please contact Abby at National Equicom- 403-218-2887. I think this a very positive move by the company to hear how shareholders feel they are doing. So please take the time to call and let her know your opinions of how IPCI is doing. I did so this morning and the questions she asked were very pertinent to some of the issues raised on this forum. If you have the time to complain on this board about IPCI, you have the 10-20 minutes it will take to get these opinions voiced to IPCI management!

Yeah keep buying before bad news tilator...

Angelo- Yeah but... If none buys their shorts right now, they won't have reason to walk down. And if no one sells after Rexista rejection, they won't be able to cover! I am not talking the momentum shorts. I am talking the guys that are manipulating IPCI every day of the week...

It should be priced in but manipulation will take it lower. That is the plan... The only thing that can prevent this is for people not to have bought the shares sold short. But I am guessing many already have and that will propel the walk down and the cover. If buyers step in as they are walking this down by wash trading, these guys won't be able to walk it down very far as they will be losing shares. My guess is they start this whole thing out with a big sell the morning of the news. Which will in turn lead to more panic selling. Then volume will subside and they will wash trade this down on low volume. They will then try to start covering end of day. This likely will continue for a couple days until they cover fully.

wimike- Yep you know who it is. This is a short sale attempt prior to bad news. Like I am telling everyone, wait until Rexista decision comes before buying. Only 5% chance Rexista news is positive. If it is, it is not that positive, because no partner and lawsuits. Wait... Wait... wait... Anyone telling you to buy now is shortselling.

Rumor is IPCI has contracted a company to do a shareholder survey to gain feedback on several items. I believe this could be a step in right direction.

tilator- sounds like you are selling.

How many posts have you made? 3??? New ID... What was your old ID?

Buying right now is a mistake unless you want to feed the shorts... Remember their goal is to sell shares now, walk this down on rejection and cover when people panic sell. If they can't sell shares now, then they don't need to walk down to cover. And remember when they walk it down, it is one hand feeding the other... If people step in and buy at that point, they will not get the shares they need to cover. And they will lose a bunch of shares along the way... As to keep the PPS low they will need to continue to wash trade.

Good job for your bro in law on the musky. I have gotten some nice ones recently too. Keep hanging in there Mike, I am really hoping brighter days ahead. I think everyone needs to do what they can not to spoon feed the shorts. DONT BUY RIGHT NOW AND DONT SELL AFTER REXISTA REJECTION. Instead buy after they walk this puppy down after Rexista rejection.

Everybody just hold pat. No buying and no selling. Let them just wash trade this thing with no net outcome. And if you held this far don't sell on Rexista rejection(I venture 95% chance of this). They want you too... As they need those shares to cover what they have been short selling recently. Let them wash trade it down on the rejection. But if you don't sell, there will be no net gain and they won't be able to cover at a profit. Then when it finds a bottom, load up. I am planning too. I have lots of cash waiting and I plan to more than triple my position. Here is the kicker. Q3 won't meet analysts expectations but will show improvement. But I think Q4 could meet analysts expectations and show a profitable quarter. Lastly, I think there is good likelihood that one of the other MNK partnered drugs gains approval prior to end of 2017.

Doog- My guess is they have been short selling. They will continue until the news on Rexista. Which will likely be a CRL. Then they will drive it down 10-20% and cover. Next order of business will be to pump and get the stock to move a little higher. Short sell again and then pound it down on Q3 earnings due to them not meeting the analysts expectations of a $4-5M quarter. Lastly, dilution could happen any day as well. They need cash and at some point that shoe will drop as well.

Angelo- nice job on the spreadsheet. I also think the way you modeled the growth to estimate Oct and Nov numbers looks reasonable. I am starting to think 40% is possible early on if that includes cost recovery. Fred makes a good case for that.

Fred- I have a question for you. What is your expectation for IPCI's cut of the MNK Seroquel XR gross revenue? Just an educated guess based on what you have seen in similar situations is fine. I am crudely guessing IPCI will see roughly 25% of the total gross MNK revenue. That 25% includes both profit sharing and costs/plus monies. So if Q3 total revenues for MNK were $1.5M, I see IPCI getting $375K total for that quarter.

doog- OK, OK, OK... I will believe it when I see it...

Part of the problem with this stock is unrealistic expectations. I have a problem with people posting that IPCI will get 40-50% of the gross revenue on Seroquel XR. I know it is the bottom of the barrel analysts that started this crap but people don't have to keep promoting these unrealistic expectations. It will only hurt the shareholders when the shorters use this info to take the price down.

Angelo- We will soon know if 40-50% of the total revenue is a realistic cut... I want to believe... But I do not.

I am going out on a limb with an estimate... I think IPCI will roughly see revenue of 25% of MNK's total sales for Seroquel XR. This revenue is both for profit sharing and costs plus. So to get to the $3M per quarter- which I think is what they will achieve. We need to see $12M in MNK Seroquel sales per quarter($4M per month). Based on the numbers Fred is posting from Symphony. I see us finally hitting this level in about 10-12 weeks. So we are getting there!

Thanks Fred, keep the weekly reports coming! I agree good momentum on market penetration.

Doog- You don't need to continue looking as what you pasted is about the most you will find. I am still waiting for Angelo to show me something that supports what he said.

All that being said. I feel there is a possibility that the cost recovery payments come in the form of a higher share of profits until the cost recovery money is exhausted. But like I said, that is just a guess on my part and IPCI never came out and said this. If what I said holds merit, initial IPCI profit share percentages will be higher than long term percentages(after the cost recovery is exhausted). So it is wise to keep that in mind when determining what IPCI's long term cut will be.

Doog and Angelo- Please point to me where you guys read or heard on how the $11M cost recovery works? I do not remember the company ever coming out and officially commenting on this. Did I miss something?

Doog- I do not for one second believe the revenue split is as high as 50/50... However... We also have the cost recovery payments from MNK... A reasonable guess would be these will be distributed as a higher share of profits until the amount that can be recovered for that specific drug is recouped. So it is possible... IPCI will be getting a better share of the profits initially. But that % will tail off once the amount specified for that drug is recouped.

Doog- IPCI Focalin XR revenues for Q3 will be lower than Q2. If the other two doses would have launched, they might have been equal, but they did not. The numbers posted by Fred confirm that PARs sale of Focalin was lower in Q3 when compared to Q2.

Fred- I am talking $3M in revenue for IPCI. The total revenue is about $3M. But that has to be somehow split between IPCI and MNK. It would be nice to know what the split is...

Mackie's numbers are just wrong... I said a while ago that Seroquel XR would be a $3M per quarter drug for IPCI and that Mackie and others were way overestimating. I now am hoping that what we are seeing is just the ramp up period... And hope IPCI can hit $3M per quarter with Seroquel XR some time in 2018. If anyone is interested, I estimate 2018 Focalin XR revenue for IPCI to be about $5M. This estimate relies on PAR launching last two doses before end of 2017. If no launch, only less.

I had high hopes for Q3 revenue. But with the slow ramp up of MNK Seroquel and PAR still not launching the last two doses of Focalin XR, IPCI will be lucky to hit $2M in total quarterly revenue. My new estimate for Q3 is total revenue of between $1.5-2.25M.

So far it appears that each subsequent month was just shy of tripling previous months reported revenue.

Fred- Do you have the latest MNK numbers for Seroquel XR? Also, is that free or paid service you see those through? If free, can you post link?